CHEMICALLY MODIFIED MESSENGER RNA'S

This invention provides messenger RNA (mRNA) molecules comprising comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	NAKAJIMA, Katsumasa, CAPLAN, Shari Lynn
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA DERIVATIVES THEREOF ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS SUGARS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	NAKAJIMA, Katsumasa CAPLAN, Shari Lynn
description	This invention provides messenger RNA (mRNA) molecules comprising comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules. La présente invention concerne des molécules d'ARN messager (ARNm) comprenant un cadre de lecture ouvert qui code pour une protéine d'intérêt, ledit ARN modifié comprenant un nucléoside sélectionné dans le groupe constitué de : (I), (II), et (III), des vecteurs de thérapie génique les comprenant, des procédés de synthèse associés, et des procédés de remplacement génique, de thérapie génique, de silençage de la transcription génique et d'administration de protéines thérapeutiques au tissu in vivo, comprenant les molécules. La présente invention concerne également des procédés de réduction de l'immunogénicité de molécules d'ARNm.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2017153936A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2017153936A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2017153936A13</originalsourceid><addsrcrecordid>eNrjZFB29nD19XR29PGJVPD1d_F083R1UfB1DQ529XN3DVII8nNUD-ZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGhuaGpsaWxmaOhsbEqQIA1akjhA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CHEMICALLY MODIFIED MESSENGER RNA'S</title><source>esp@cenet</source><creator>NAKAJIMA, Katsumasa ; CAPLAN, Shari Lynn</creator><creatorcontrib>NAKAJIMA, Katsumasa ; CAPLAN, Shari Lynn</creatorcontrib><description>This invention provides messenger RNA (mRNA) molecules comprising comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules. La présente invention concerne des molécules d'ARN messager (ARNm) comprenant un cadre de lecture ouvert qui code pour une protéine d'intérêt, ledit ARN modifié comprenant un nucléoside sélectionné dans le groupe constitué de : (I), (II), et (III), des vecteurs de thérapie génique les comprenant, des procédés de synthèse associés, et des procédés de remplacement génique, de thérapie génique, de silençage de la transcription génique et d'administration de protéines thérapeutiques au tissu in vivo, comprenant les molécules. La présente invention concerne également des procédés de réduction de l'immunogénicité de molécules d'ARNm.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; DERIVATIVES THEREOF ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; NUCLEIC ACIDS ; NUCLEOSIDES ; NUCLEOTIDES ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; SUGARS ; VINEGAR ; WINE</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170914&DB=EPODOC&CC=WO&NR=2017153936A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170914&DB=EPODOC&CC=WO&NR=2017153936A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>NAKAJIMA, Katsumasa</creatorcontrib><creatorcontrib>CAPLAN, Shari Lynn</creatorcontrib><title>CHEMICALLY MODIFIED MESSENGER RNA'S</title><description>This invention provides messenger RNA (mRNA) molecules comprising comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules. La présente invention concerne des molécules d'ARN messager (ARNm) comprenant un cadre de lecture ouvert qui code pour une protéine d'intérêt, ledit ARN modifié comprenant un nucléoside sélectionné dans le groupe constitué de : (I), (II), et (III), des vecteurs de thérapie génique les comprenant, des procédés de synthèse associés, et des procédés de remplacement génique, de thérapie génique, de silençage de la transcription génique et d'administration de protéines thérapeutiques au tissu in vivo, comprenant les molécules. La présente invention concerne également des procédés de réduction de l'immunogénicité de molécules d'ARNm.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>DERIVATIVES THEREOF</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>NUCLEIC ACIDS</subject><subject>NUCLEOSIDES</subject><subject>NUCLEOTIDES</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>SUGARS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFB29nD19XR29PGJVPD1d_F083R1UfB1DQ529XN3DVII8nNUD-ZhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfHh_kYGhuaGpsaWxmaOhsbEqQIA1akjhA</recordid><startdate>20170914</startdate><enddate>20170914</enddate><creator>NAKAJIMA, Katsumasa</creator><creator>CAPLAN, Shari Lynn</creator><scope>EVB</scope></search><sort><creationdate>20170914</creationdate><title>CHEMICALLY MODIFIED MESSENGER RNA'S</title><author>NAKAJIMA, Katsumasa ; CAPLAN, Shari Lynn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2017153936A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2017</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>DERIVATIVES THEREOF</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>NUCLEIC ACIDS</topic><topic>NUCLEOSIDES</topic><topic>NUCLEOTIDES</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>SUGARS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>NAKAJIMA, Katsumasa</creatorcontrib><creatorcontrib>CAPLAN, Shari Lynn</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>NAKAJIMA, Katsumasa</au><au>CAPLAN, Shari Lynn</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CHEMICALLY MODIFIED MESSENGER RNA'S</title><date>2017-09-14</date><risdate>2017</risdate><abstract>This invention provides messenger RNA (mRNA) molecules comprising comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules. La présente invention concerne des molécules d'ARN messager (ARNm) comprenant un cadre de lecture ouvert qui code pour une protéine d'intérêt, ledit ARN modifié comprenant un nucléoside sélectionné dans le groupe constitué de : (I), (II), et (III), des vecteurs de thérapie génique les comprenant, des procédés de synthèse associés, et des procédés de remplacement génique, de thérapie génique, de silençage de la transcription génique et d'administration de protéines thérapeutiques au tissu in vivo, comprenant les molécules. La présente invention concerne également des procédés de réduction de l'immunogénicité de molécules d'ARNm.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng ; fre
recordid	cdi_epo_espacenet_WO2017153936A1
source	esp@cenet
subjects	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA DERIVATIVES THEREOF ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS SUGARS VINEGAR WINE
title	CHEMICALLY MODIFIED MESSENGER RNA'S
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T16%3A07%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=NAKAJIMA,%20Katsumasa&rft.date=2017-09-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2017153936A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true